236 related articles for article (PubMed ID: 16198578)
1. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Itoh T; Murota I; Yoshikai K; Yamada S; Yamamoto K
Bioorg Med Chem; 2006 Jan; 14(1):98-108. PubMed ID: 16198578
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
[TBL] [Abstract][Full Text] [Related]
3. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents.
Yamamoto K; Itoh T; Abe D; Shimizu M; Kanda T; Koyama T; Nishikawa M; Tamai T; Ooizumi H; Yamada S
Bioorg Med Chem Lett; 2005 Feb; 15(3):517-22. PubMed ID: 15664804
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
Itoh T; Yamamoto K
Naunyn Schmiedebergs Arch Pharmacol; 2008 Jun; 377(4-6):541-7. PubMed ID: 18193404
[TBL] [Abstract][Full Text] [Related]
5. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Liu W; Lau F; Liu K; Wood HB; Zhou G; Chen Y; Li Y; Akiyama TE; Castriota G; Einstein M; Wang C; McCann ME; Doebber TW; Wu M; Chang CH; McNamara L; McKeever B; Mosley RT; Berger JP; Meinke PT
J Med Chem; 2011 Dec; 54(24):8541-54. PubMed ID: 22070604
[TBL] [Abstract][Full Text] [Related]
6. Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPARγ partial agonists.
Furukawa A; Arita T; Fukuzaki T; Satoh S; Mori M; Honda T; Matsui Y; Wakabayashi K; Hayashi S; Araki K; Ohsumi J
Bioorg Med Chem Lett; 2012 Feb; 22(3):1348-51. PubMed ID: 22225641
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators.
Kumar R; Mittal A; Ramachandran U
Bioorg Med Chem Lett; 2007 Aug; 17(16):4613-8. PubMed ID: 17574414
[TBL] [Abstract][Full Text] [Related]
8. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.
Lin CH; Peng YH; Coumar MS; Chittimalla SK; Liao CC; Lyn PC; Huang CC; Lien TW; Lin WH; Hsu JT; Cheng JH; Chen X; Wu JS; Chao YS; Lee HJ; Juo CG; Wu SY; Hsieh HP
J Med Chem; 2009 Apr; 52(8):2618-22. PubMed ID: 19301897
[TBL] [Abstract][Full Text] [Related]
9. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.
Yamazaki Y; Kawano Y; Uebayasi M
Life Sci; 2008 Jan; 82(5-6):290-300. PubMed ID: 18166202
[TBL] [Abstract][Full Text] [Related]
10. Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma.
Gani OA; Sylte I
Chem Biol Drug Des; 2008 Jul; 72(1):50-7. PubMed ID: 18554251
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) γ Agonists.
Rikimaru K; Wakabayashi T; Abe H; Tawaraishi T; Imoto H; Yonemori J; Hirose H; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 May; 20(10):3332-58. PubMed ID: 22503460
[TBL] [Abstract][Full Text] [Related]
12. Docosahexaenoic acid regulates adipogenic genes in myoblasts via porcine peroxisome proliferator-activated receptor gamma.
Yu YH; Lin EC; Wu SC; Cheng WT; Mersmann HJ; Wang PH; Ding ST
J Anim Sci; 2008 Dec; 86(12):3385-92. PubMed ID: 18676720
[TBL] [Abstract][Full Text] [Related]
13. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation.
Ye F; Zhang ZS; Luo HB; Shen JH; Chen KX; Shen X; Jiang HL
Chembiochem; 2006 Jan; 7(1):74-82. PubMed ID: 16317783
[TBL] [Abstract][Full Text] [Related]
14. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
15. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
[TBL] [Abstract][Full Text] [Related]
17. A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) γ agonists: design and synthesis of benzylpyrazole acylsulfonamides.
Rikimaru K; Wakabayashi T; Abe H; Imoto H; Maekawa T; Ujikawa O; Murase K; Matsuo T; Matsumoto M; Nomura C; Tsuge H; Arimura N; Kawakami K; Sakamoto J; Funami M; Mol CD; Snell GP; Bragstad KA; Sang BC; Dougan DR; Tanaka T; Katayama N; Horiguchi Y; Momose Y
Bioorg Med Chem; 2012 Jan; 20(2):714-33. PubMed ID: 22209730
[TBL] [Abstract][Full Text] [Related]
18. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
[TBL] [Abstract][Full Text] [Related]
20. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
